Public Employees Retirement System of Ohio Increases Stake in Bio-Rad Laboratories, Inc. $BIO

Public Employees Retirement System of Ohio grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 6,307 shares of the medical research company’s stock after buying an additional 218 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Bio-Rad Laboratories were worth $1,522,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Bio-Rad Laboratories by 20.9% during the second quarter. GAMMA Investing LLC now owns 734 shares of the medical research company’s stock worth $177,000 after purchasing an additional 127 shares during the last quarter. UMB Bank n.a. lifted its stake in Bio-Rad Laboratories by 89.8% during the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after purchasing an additional 79 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Bio-Rad Laboratories by 123.4% during the second quarter. Exchange Traded Concepts LLC now owns 13,932 shares of the medical research company’s stock worth $3,362,000 after purchasing an additional 7,697 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Bio-Rad Laboratories during the second quarter worth approximately $238,000. Finally, Harbor Capital Advisors Inc. lifted its stake in Bio-Rad Laboratories by 2.0% during the second quarter. Harbor Capital Advisors Inc. now owns 9,254 shares of the medical research company’s stock worth $2,233,000 after purchasing an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

BIO has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Saturday, September 27th. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $333.50.

Bio-Rad Laboratories Trading Up 3.8%

NYSE:BIO opened at $305.47 on Friday. The firm has a market cap of $8.27 billion, a P/E ratio of 26.04 and a beta of 0.97. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The stock’s 50 day simple moving average is $281.55 and its 200-day simple moving average is $254.72. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same quarter in the prior year, the company posted $3.11 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 2.1% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.